Gilead's idelalisib hat trick

Share this article:

Gilead's Zydelig, formerly known as idelalisib, has been approved. The FDA greenlighted the drug for three cancers: chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma.

Zydelig is a first-in-class phosphoinositide 3-kinase delta inhibitor. The drug snared breakthrough status for the CLL indication. Despite the first-in-class status, the drug already has competition, including CLL drugs Imbruvica (Johnson & Johnson) and Roche's Gazyva.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters